Journal article · 2017 · Open access

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Paul M. Ridker, Brendan M. Everett, Tom Y. Thuren, Jean G. MacFadyen, William H. Chang, Christie Mitchell Ballantyne, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Wolfgang Köenig, Stefan D. Anker, John J.P. Kastelein, Jan Hein Cornel and 16 more

New England Journal of Medicine, 377(12), 1119–1131 · Published 27 August 2017 · DOI 10.1056/nejmoa1707914

Free PDFView at the publisherCite this paper

In brief

“Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease” is a 2017 journal article by Paul M. Ridker and 27 co-authors, published in New England Journal of Medicine. OpenAlex counts 9,911 citations as of 15 November 2026. It is open access: the full text is free to read at New England Journal of Medicine.

Citations
9,911
Most cited in
2026 (1,371)
Field-weighted impact
361.36
References
40
Authors
28

Abstract

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ridker, P. M., Everett, B. M., Thuren, T. Y., MacFadyen, J. G., Chang, W. H., Ballantyne, C. M., Fonseca, F. A. H., Nicolau, J. C., Köenig, W., Anker, S. D., Kastelein, J. J., Cornel, J. H., Pais, P., Pella, D., Genest, J. J., Cífková, R., Lorenzatti, A. J., Forster, T., Kobalava, Z. D., . . . Glynn, R. J. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 377(12), 1119–1131. https://doi.org/10.1056/nejmoa1707914

MLA 9

Ridker, Paul M., et al. “Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.” New England Journal of Medicine, vol. 377, no. 12, 2017, pp. 1119–1131. https://doi.org/10.1056/nejmoa1707914.

Chicago

Ridker, Paul M., Brendan M. Everett, Tom Y. Thuren, Jean G. MacFadyen, William H. Chang, Christie Mitchell Ballantyne, Francisco Antônio Helfenstein Fonseca, et al. 2017. “Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.” New England Journal of Medicine 377 (12): 1119–1131. https://doi.org/10.1056/nejmoa1707914.

Harvard

Ridker, P. M. et al. (2017) ‘Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease’, New England Journal of Medicine, 377(12), pp. 1119–1131. doi:10.1056/nejmoa1707914.

IEEE

P. M. Ridker et al., “Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease,” New England Journal of Medicine, vol. 377, no. 12, pp. 1119–1131, 2017, doi: 10.1056/nejmoa1707914.

BibTeX

@article{ridker2017antiinflammatory,
  title     = {{Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease}},
  author    = {Ridker, Paul M. and Everett, Brendan M. and Thuren, Tom Y. and MacFadyen, Jean G. and Chang, William H. and Ballantyne, Christie Mitchell and Fonseca, Francisco Antônio Helfenstein and Nicolau, José Carlos and Köenig, Wolfgang and Anker, Stefan D. and Kastelein, John J.P. and Cornel, Jan Hein and Pais, Prem and Pella, Daniel and Genest, Jacques J. and Cífková, Renata and Lorenzatti, Alberto J. and Forster, Tamás and Kobalava, Zhanna D. and Vida-Simiti, Luminiţa Animarie and Flather, Marcus D and Shimokawa, Hiroaki and Ogawa, Hisao and Dellborg, Mikael and Rossi, Paulo R.F. and Troquay, Roland P.T. and Libby, Peter and Glynn, Robert J.},
  journal   = {New England Journal of Medicine},
  year      = {2017},
  volume    = {377},
  number    = {12},
  pages     = {1119--1131},
  doi       = {10.1056/nejmoa1707914},
  url       = {https://doi.org/10.1056/nejmoa1707914}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
2017168168
2018855855
2019945945
20201,0801080
20211,0961096
20221,0931093
20231,0331033
20241,0471047
20251,2051205
20261,3711371

Its field-weighted citation impact is 361.36: it has been cited 361.36 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases

  • canakinumab
  • IL-1β inhibition
  • anti-inflammatory therapy
  • atherosclerosis
  • cardiovascular disease prevention
  • high-sensitivity C-reactive protein
  • myocardial infarction
  • stroke

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Ridker, P. M., Everett, B. M., Thuren, T. Y., MacFadyen, J. G., Chang, W. H., Ballantyne, C. M., Fonseca, F. A. H., Nicolau, J. C., Köenig, W., Anker, S. D., Kastelein, J. J., Cornel, J. H., Pais, P., Pella, D., Genest, J. J., Cífková, R., Lorenzatti, A. J., Forster, T., Kobalava, Z. D., . . . Glynn, R. J. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 377(12), 1119–1131. https://doi.org/10.1056/nejmoa1707914

How many times has this paper been cited?

9,911 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at New England Journal of Medicine.

Who wrote this paper?

Paul M. Ridker, Brendan M. Everett, Tom Y. Thuren, Jean G. MacFadyen, William H. Chang, Christie Mitchell Ballantyne, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Wolfgang Köenig, Stefan D. Anker, John J.P. Kastelein, Jan Hein Cornel and 16 more.

What is the DOI of this paper?

10.1056/nejmoa1707914. The permanent link is https://doi.org/10.1056/nejmoa1707914.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.